Medicine Registration and Medicine Quality: A Preliminary Analysis of Key Cities in Emerging Markets

Background: The medicine registration process is not just a matter of formality but involves assessment of medicine quality and stability. It is perhaps the most important as well as the simplest aspect of medicine regulation. This study attempts to ascertain whether registered medicines perform better in simple quality tests than those that are either not registered or not known to be registered.

Methods: Over the past 30 months, 2065 essential medicines (for treatment of malaria, tuberculosis, and bacterial infections) were procured by covert shoppers from 11 African cities and from eight cities in a variety of middle-income nations. All samples were assessed using the Global Pharma Health Fund e.V. Minilab® protocol, which includes visual inspection, semiquantitative thin-layer chromatography, and disintegration testing, to identify whether they were substandard, degraded, or counterfeit.

Results: Where medicine registration data were available, 1940 medicines were identified, of which 1589 were registered and 351 were either unregistered or not known to be registered. The failure rate among registered medicines was 5% (79/1589) and 37.3% (131/351) amongst medicines that were either unregistered or not known to be registered. African cities had fewer medicines registered (71%, or 488/687) than Indian cities (86.9%, or 610/702) or other middle-income cities (89.1%, or 491/551). Samples from African cities performed far worse in quality tests (18.6% failed, or 128/687) than either samples from Indian cities (8.7% failed, or 61/702) or other middle-income cities (3.8% failed, or 21/551). There was also a notable disparity in failure rates by medicine type; 14.2% (101/710) of antimalarials failed testing, 10.1% (70/693) of antibiotics failed, and 7.3% (39/537) of antimycobacterials failed.

Conclusion: The results strongly indicate that medicine registration is an important component of better-quality medicines. Registered medicines performed better than unregistered medicines, and the result was strongly statistically significant.

View the full report as an Adobe Acrobat PDF.

Roger Bate is the Legatum Fellow in Global Prosperity at AEI.

Photo Credit: iStockphoto/Kenneth C. Zirkel

Also Visit
AEIdeas Blog The American Magazine
About the Author

 

Roger
Bate

What's new on AEI

Holder will regret his refusal to obey the Constitution
image 'Flood Wall Street' climate protesters take aim at their corporate allies
image 3 opportunities for better US-India defense ties
image Is Nicolás Maduro Latin America's new man at the United Nations?
AEI on Facebook
Events Calendar
  • 29
    MON
  • 30
    TUE
  • 01
    WED
  • 02
    THU
  • 03
    FRI
Thursday, October 02, 2014 | 9:00 a.m. – 10:30 a.m.
Campbell Brown talks teacher tenure

We welcome you to join us as Brown shares her perspective on the role of the courts in seeking educational justice and advocating for continued reform.

Friday, October 03, 2014 | 12:00 p.m. – 1:00 p.m.
Harnessing the power of markets to tackle global poverty: A conversation with Jacqueline Novogratz

AEI welcomes you to this Philanthropic Freedom Project event, in which Novogratz will describe her work investing in early-stage enterprises, what she has learned at the helm of Acumen, and the role entrepreneurship can play in the fight against global poverty.

No events scheduled this day.
No events scheduled this day.
No events scheduled this day.
No events scheduled today.
No events scheduled this day.
No events scheduled this day.